Adrian Senderowicz
Director/Board Member at PUMA BIOTECHNOLOGY, INC.
Net worth: 131 760 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alan Auerbach | M | 54 | 14 years | |
| Tina Bjørnlund Bønsdorff | M | 53 |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Erik van den Berg | M | 51 |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | 8 years |
| Michael Miller | M | 67 | 6 years | |
| Brian Stuglik | M | 64 | 4 years | |
| Vanessa Malier | F | 51 |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Thora Johanna Jonasdottir | M | 59 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Jay Moyes | M | 70 | 12 years | |
| Troy Wilson | M | 55 | 11 years | |
| Alessandra Cesano | M | 63 | 2 years | |
| Jacky Vonderscher | M | 69 |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Andrew Parker | M | 59 |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | 5 years |
| Maximo Nougues | M | 55 | 6 years | |
| Allison Dorval | F | 48 | 3 years | |
| Sylvain Latour | M | - |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Douglas Hunt | M | 59 | 6 years | |
| Anders Månsson | M | 57 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 1 years |
| Christine Mauck | M | - | 8 years | |
| Jeffrey Ludwig | M | 58 | 4 years | |
| Alvin Wong | M | 71 | 11 years | |
| Jacob Lange Moresco | M | - |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Susan Mary Galbraith | M | - | 14 years | |
| Alain Fischer | M | - |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Mariann Ohanesian | F | - | - | |
| Thibaut Roulon | M | - |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Leiv Askvig | M | 67 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | - |
| Adrian Charles Noel Kemp | M | 58 | 15 years | |
| Louis Joseph Nisbet | M | - |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Simon Hirst | M | 60 |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | - |
| Josie Afolabi | F | - | 14 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Charles R. Eyler | M | 76 | 8 years | |
| Emma Reeve | F | 63 | 4 years | |
| Steven Hoerter | M | 53 | 5 years | |
| Paul Friedman | M | 81 |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| James Ward-Lilley | M | 59 | 1 years | |
| Menelas Pangalos | M | 57 | 13 years | |
| Roy Hartvig Larsen | M | 62 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 14 years |
| Donald Bruce Burlington | M | 75 | 7 years | |
| David Walt | M | 71 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 2 years |
| Elizabeth G. Trehu | M | 64 | 3 years | |
| Briggs Morrison | M | 65 | 3 years | |
| Nicole P. Jones | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 1 years |
| Hugh O'Dowd | M | 59 | 2 years | |
| Steve Hall | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 6 years |
| Shriti Vadera | F | 62 | 7 years | |
| Ann Miller | M | 66 | 2 years | |
| Peter Svennilson | M | 62 | 3 years | |
| Richard Levy | M | 66 | 1 years | |
| Scott Braunstein | M | 60 | 2 years | |
| Rudolph Markham | M | 78 | 11 years | |
| Mishima Gerhart | F | - | 6 years | |
| Frank Zavrl | M | 58 | 5 years | |
| Anthony Evnin | M | 83 | 12 years | |
| Susan Kelley | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| Cheryl Collett | F | - | - | |
| Edward Bradley | M | - | - | |
| Antoine Yver | M | 66 | 7 years | |
| Sun Park | M | 47 | 1 years | |
| Adrian Marsh | M | 58 | 6 years | |
| Andrea Dunstan | F | 64 | 5 years | |
| Richard Benton Phillips | M | 70 | - | |
| Erin Jones | M | 52 | 2 years | |
| Robert Wild | M | 53 | 2 years | |
| Alejandra Carvajal | F | 50 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| Elaine Sullivan | M | 63 | 15 years | |
| Alison Armour | M | 60 | 7 years | |
| Marion McCourt | F | 64 | 2 years | |
| Brian Barnett | M | 53 | 3 years | |
| Martin Brenner | M | 54 | 1 years | |
| Sharon Benzeno | M | 50 | 6 years | |
| John Gustofson | M | - | 4 years | |
| Jeffrey Humphrey | M | 62 | 1 years | |
| Karin Ann Thacker | F | - | 1 years | |
| Ronan O’Brien | M | 52 | 2 years | |
| Rahul Kakkar | M | 49 | 4 years | |
| Steven Lo | M | 57 | 4 years | |
| Rajesh Chopra | M | 63 | 5 years | |
| John Geoffery Goddard | M | 73 | 4 years | |
| John Gordon Buchanan | M | 79 | 8 years | |
| Håkan Lars Mogren | M | 79 | 10 years | |
| Jane Ellen Henney | M | 76 | 10 years | |
| Peter Kiener | M | 72 | 8 years | |
| Bruno Francois Jules Angelici | M | 77 | 21 years | |
| Graeme H. R. Musker | M | - | 16 years | |
| Jan Lundberg | M | 71 | 11 years | |
| Anthony Zook | M | 63 | 3 years | |
| Martin MacKay | M | 68 | 3 years | |
| David Elkins | M | 55 | 2 years | |
| Glenn A. Miller | M | - | - | |
| Jan Alan Alfheim | M | - |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | 7 years |
| James Ferguson | M | 70 | 6 years | |
| Reginald Seeto | M | 52 | 5 years | |
| John Patterson | M | 76 | - | |
| Jónas Einarsson | M | 67 |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | - |
| Esra Erkal-Paler | F | - | 7 years | |
| Marc J. Wolfgang | M | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 1 years |
| Alan Barge | M | - | 1 years | |
| Edward Garmey | M | 56 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 4 years |
| José Antonio Toledo Vieira | M | 59 | 2 years | |
| Paul Reider | M | 55 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 42 | 42.00% |
| United Kingdom | 40 | 40.00% |
| France | 11 | 11.00% |
| Norway | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Adrian Senderowicz
- Personal Network
